KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Average (2016 - 2025)

Historic Equity Average for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $511.5 million.

  • Alnylam Pharmaceuticals' Equity Average rose 92881.08% to $511.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $511.5 million, marking a year-over-year increase of 92881.08%. This contributed to the annual value of $428.1 million for FY2025, which is 65762.33% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Equity Average stood at $511.5 million, which was up 92881.08% from $242.2 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Equity Average's 5-year high stood at $971.2 million during Q1 2021, with a 5-year trough of -$333.7 million in Q2 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Equity Average value was $72.7 million (recorded in 2022), while the average stood at $190.0 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Equity Average plummeted by 62950.78% in 2023, and later skyrocketed by 155426.64% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Equity Average stood at $672.0 million in 2021, then crashed by 116.8% to -$112.9 million in 2022, then tumbled by 71.13% to -$193.3 million in 2023, then surged by 125.73% to $49.7 million in 2024, then soared by 928.81% to $511.5 million in 2025.
  • Its Equity Average was $511.5 million in Q4 2025, compared to $242.2 million in Q3 2025 and $183.0 million in Q2 2025.